FactorPad
Build a Better Process

Stock Risk Measures for Ultragenyx Pharmaceutical In

A quantitative factor review, as of September 30, 2020.
  1. Company Info - Description, identity and sector data.
  2. Share Data - Stock earnings and key dates.
  3. Market Risk - Beta, size, liquidity and momentum measures.
  4. Financial Risk - Earnings and dividends.
by Paul Alan Davis, CFA
Updated: October 01, 2020
See how we arrive at an overall risk score of 50 for RARE below.

/ factorpad.com / stocks / f61ksd.html


An ad-free and cookie-free webpage by FactorPad


RARE Risk Report

Overview

Our quantitative data points are meant to provide a high-level understanding of factors in equity risk models for Ultragenyx Pharmaceutical In. Portfolio managers use these models to forecast risk, optimize portfolios and review performance.

We show how RARE stock compares to 2,000+ US-based stocks, and to peers in the Health Technology sector and Biotechnology industry.

Please do not consider this data as investment advice. Data is downloaded from sources we deem reliable, but errors may occur.

Company Info

Business Description

Company logo Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

Identity

Sector and Industry

Share Data

Shares and Float

Earnings and Dividends

Market Risk Measures

Many of the following risk metrics are standardized and transformed into quantitative factors in institutional-level risk models.

Rankings below represent percentiles from 1 to 100, with 1 being the lowest rating of risk.

Systematic Risk

Stocks with higher beta exhibit higher sensitivity to the ups and downs in the market. (↑↑)

Company Size

Stocks with higher market capitalization often have lower risk. (↑↓)

Trading Liquidity

Higher average daily dollar volume over the past 30 days implies lower liquidity risk. (↑↓)

Price Momentum

Higher price momentum stocks, aka recent winners, equate to lower risk for many investors. (↑↓)

Financial Risk Measures

Style risk factors often include measures of profitability and payout levels.

Earnings Yield

Companies with higher earnings generally provide lower risk. (↑↓)

Dividend Yield

Companies with higher dividend yields, if sustaintable, are perceived to have lower risk. (↑↓)

/ factorpad.com / stocks / f61ksd.html


RARE stock risk
ULTRAGENYX PHARMACEUTICAL IN stock beta
RARE risk report
RARE f61ksd
RARE risk analysis
RARE volatility
ULTRAGENYX PHARMACEUTICAL IN credit risk
RARE liquidity risk
RARE leverage
RARE valuation
RARE systematic risk
RARE specific risk
ULTRAGENYX PHARMACEUTICAL IN volatility
RARE analysis
RARE financial ratio

This is a new resource, spread the word, tell a friend